ssr节点2025每日更新
ssr节点2025每日更新
Luis
Supply Chain at Apellis
ssr节点2025每日更新
Learn More
ssr节点2025每日更新
ssr节点2025每日更新
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
ssr节点2025每日更新
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
w加速器官网
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
@ApellisPharma
ssr节点2025每日更新
FOR PATIENTS
ssr节点2025每日更新
for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.
ssr节点2025每日更新
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.
CLINICAL TRIALSssr节点2025每日更新
so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike
We challenge conventional thinking and always question if there's a better way.
Join Us
Patricia
Quality Assurance at Apellis
This website is intended for residents of the U.S.